Aldeyra Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Aldeyra Therapeutics

04/05/2023 14:09

* Aldeyra Therapeutics Inc  ALDX.OQ  reported a quarterly
adjusted
loss of 27 cents​​ per share for the quarter ended in March. The
mean expectation of eight analysts for the quarter was for a
loss of 29 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Aldeyra Therapeutics Inc's reported EPS for the quarter
was a
loss of 27 cents​.
    * The mean earnings estimate of analysts had risen by
about 33.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aldeyra Therapeutics Inc shares had risen by 2.5% this
quarter and gained 46.3% so far this year.
    * The company reported a quarterly loss of $15.62 million.
    * Wall Street's median 12-month price target for Aldeyra
Therapeutics Inc is $17.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 01:09 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.29          -0.27          Beat
 Dec. 31 2022      -0.31          -0.22          Beat
 Sep. 30 2022      -0.34          -0.25          Beat
 Jun. 30 2022      -0.31          -0.30          Beat